Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken orally.
Razpipadon acts as a selective partial agonist of the dopamine D<sub>1</sub> and D<sub>5</sub> receptors.
The drug was originated by Pfizer and is under development by Cerevel Therapeutics. As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.